Abstract
Since the advent of hybridoma technology, mammalian-cell culture has been employed for the expression and high-level production of monoclonal antibodies (MAbs). Recent adaptations in recombinant technology have developed the use of numerous prokaryotic and eukaryotic systems for the expression of heterologous molecules. The major systems used for MAb expression have been reviewed and compared (1,2), and a number of the key methodologies are detailed within this series. Prokaryotic expression systems offer the potential of high production yields at a substantial reduced cost of goods (see Chapter 14). However, because of the complexity of the protein-folding pathway, bacterial expression has been limited to small antibody fragments, and in some cases may require refolding to produce a biologically active product. Another limitation is that recombinant MAbs expressed in bacteria are aglycosylated and can result in the reduction or loss of biological effector functions (3). For large, multidomain molecules such as full-length MAbs or complex recombinant antibody fragments, eukaryotic systems such as mammalian or yeast expression have been utilized. Currently, nine USFDA-licensed Mabs for in vivo human use have been expressed from mammalian-cell culture for commercial production.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Verma, R., Boleti, E., and George, A.J.T. (1998) Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216, 165–181.
Geisse, S. and Kocher, H. P. (1999) Protein expression in mammalian and insect cells systems. Methods Enzymol. 306, 19–41.
Wright, A. and Morrison, S. (1997) Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 15, 26–32.
Gluzman, Y. (1981) SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23, 175–182.
Trill, J. J., Shatzman, A. R., and Ganquly, S. (1995) Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 6, 553–560.
Chu, G., Hayakawa, H., and Berg, P. (1987) Electroporation for the efficient transfection of mammalian cells with DNA. Nucleic Acids Res. 15, 1311–1326.
Kaufman, R. J. (1990) Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol. 185, 537–566.
Bebbington, C., Renner, G., Thomson, S., King, D., Abrams, D., and Yarranton, G. T. (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selection marker. Biotechnology 10, 169–175.
Urlaub, G. and Chasin, L. A. (1980) Isolation of Chinese hamster ovary cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA 77, 4216–4220.
Page, M. J., Sydenham, M.A. (1991) High level expression of a humanized monoclonal antibody CAMPATH-1H in Chinese hamster ovary cells. Biotechnology 9, 64–68.
Yoo, E. M., Chintalacharuvu, K. R., Penichet, M. L., and Morrison, S. L. (2002) Myeloma expression systems. J. Immunol. Methods 261, 1–20.
Bebbington, C. R. (1991) Expression of antibody genes in nonlymphoid mammalian cells. Methods: A Companion to Methods in Enzymology 2, 136–145.
Peakman, T. C., Worden, J., Harris, R. H., Cooper, H., Tite, J., Page, M. J., et al. (1994) Comparison of expression of a humanized monoclonal antibody in mouse NS0 myeloma cells and Chinese Hamster Ovary cells. Hum. Antibod. Hybrid. 5(1 and 2), 65–74.
Zhou, W., Chen, C., Buckland, B., and Aunins, J. (1997) Fed-batch culture of recombinant NS0 myeloma cells with high monoclonal antibody production. Biotechnol. Bioeng. 55, 783–792.
Chadd, H. E. and Chamow, S. M. (2001) Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 12, 188–194.
Chu, L. and Robinson, D. K. (2001) Industrial choices for protein production by large-scale. Curr. Opin. Biotechnol. 2, 180–187.
Shively, J. E. and Beatty, J. D. (1985) CEA-related antigens: molecular biology and clinical significance. Crit. Rev. Oncol. Hematol. 2, 355–399.
Hammarstrom, S. (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Sem. in Cancer Biol. 9, 67–81.
Wu, A. M. and Yazaki, P. J. (2000) Designer genes: recombinant antibody fragments for biological imaging. Quarterly Journal of Nuclear Medicine 44, 268–283.
Goldenberg, D. M. (2002) Targeted therapy of cancer with radiolabeled antibodies. Journal of Nuclear Medicine 43, 693–713.
Wagener, C., Yang, Y.H.J., Crawford, F. G., and Shively, J. E. (1983) Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: a systematic approach for the determination of epitope specificities of monoclonal antibodies. J. Immunol. 130, 2308–2315.
Neumaier, M., Fenger, U., and Wagener, C. (1985) Monoclonal antibodies for carcinoembryonic antigen (CEA) as a model system: identification of two novel CEA-related antigens in meconium and colorectal carcinoma tissue by Western blots and differential immunoaffinity chromatography. J. Immunol. 135, 3604–3609.
Wu, A. M., Williams, L. E., Zieran, L., Padma, A., Sherman, M., Bebb, G. G., et al. (1999) Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 4, 1–12.
Hu, S.-Z., Shively, L., Raubitschek, A. A., Sherman, M., Williams, L. E., Wong, J.Y.C., et al. (1996) Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid high-level targeting of xenografts. Cancer Res. 56, 3055–3061.
Xu, X., Clarke, P., Szalai, G., Shively, J. E., Williams, L. E., Shyr, Y., et al. (2000) Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. 60, 4475–4484.
Yazaki, P. J., Shively, L., Clark, C., Cheung, C.-W., Le, W., Szpikowska, B., et al. (2001) Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods 253, 195–208.
Laemmli, U. (1970) Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 227, 680–685.
Towbin, H., Staehelin, T., and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc. Natl. Acad. Sci. USA 76, 4350–4354.
Gagnon, P. (1996) Purification tools for monoclonal antibodies. Validated Biosystems, Tuscon, AZ.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Yazaki, P.J., Wu, A.M. (2004). Expression of Recombinant Antibodies in Mammalian Cell Lines. In: Lo, B.K.C. (eds) Antibody Engineering. Methods in Molecular Biology™, vol 248. Humana Press. https://doi.org/10.1385/1-59259-666-5:255
Download citation
DOI: https://doi.org/10.1385/1-59259-666-5:255
Publisher Name: Humana Press
Print ISBN: 978-1-58829-092-2
Online ISBN: 978-1-59259-666-9
eBook Packages: Springer Protocols